glp-1 colorectal cancer mortality study november 2025 Weight-Loss Meds Linked to Improved Colon Survival Association between GLP-1 receptor agonists

The Wegovy stomach paralysis lawsuit alleges that Novo Nordisk, the manufacturer, failed to adequately warn patients about these severe side effects, leading to numerous Ozempic stomach paralysis lawsuits and ongoing litigation

Clinical Evidence and FDA Status Comparison Tesamorelin has robust FDA approval for lipodystrophy-associated visceral adiposity in HIV-positive adults

Plaidum S, Patcharatrakul T, Promjampa W, Gonlachanvit S

In this article, we will examine how these medications affect not only hunger but also habits and urges

While in some cases these standards go beyond what may be required by law, we believe that they raise the bar in helping instill trust and confidence in our offerings

In May 2024, as second study in the New England Journal of Medicine found that the risk of a primary heart or kidney event was 24% lower in the semaglutide group